Cytovas, LLC - 19104 Philadelphia, PA

Business Name: Cytovas, LLC
Categorized In: Research and Development Laboratories
Address: 3160 Chestnut Street # 200, Philadelphia, PA 19104
Phone Number: (215) 662-3275
Contact Person: Pascal Yvon
Website Address: cytovas.com
Business Type: B2B (Business to Business)
Founding Year: 2011
Employee #: 1 to 4
Location Type: Single Location
Annual Revenue ($): Unknown
Share This Business:
Similar Businesses: Fibradigm Therapeutics LLC - Philadelphia, PA 19104
Cellulosic Biotherapeutics LLC - Philadelphia, PA 19104
Axonia Medical LLC - Philadelphia, PA 19104
Micropathid D Iagnostics LLC - Philadelphia, PA 19104
Myostratum LLC - Philadelphia, PA 19104
Neuronai LLC - Philadelphia, PA 19104
Invidisyn LLC - Philadelphia, PA 19104
Oxygense - Philadelphia, PA 19104
Relgene LLC - Philadelphia, PA 19104
Translatum LLC - Philadelphia, PA 19104
Biosucran - Philadelphia, PA 19104
Sante Biosciences - Philadelphia, PA 19104
Cognizance Biomarkers LLC - Philadelphia, PA 19104
Wilson Robert D MD - Philadelphia, PA 19104
Graphene Frontiers LLC - Philadelphia, PA 19104
Anosos Biotherapeutics LLC - Philadelphia, PA 19104
Sunstone Biosciences Inc - Philadelphia, PA 19104
Quern Therapeutics - Philadelphia, PA 19104
Innofect - Philadelphia, PA 19104
Mitergy LLC - Philadelphia, PA 19104

Cytovas, LLC provides professional Research and Development Laboratories from its single location at the coordinates 39.9536,-75.18595.

The company offers B2B variables under the SIC code and NAICS code , while making an annual revenue of Unknown and hiring a total of 1 to 4 employees.

Founded in 2011, the company can now be visited at 3160 Chestnut Street # 200, Philadelphia, Pennsylvania 19104 or contacted through representative Pascal Yvon at (215) 662-3275.

For frequently asked questions and further inquiries about professional Research and Development Laboratories, get to know more about Cytovas, LLC through its company website at cytovas.com. Engage with this business on its social media platforms through on Twitter and on Facebook.